Carfilzomib

卡非佐米

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameCarfilzomib
Drug Alias NameCarfilzomibumKyprolisONO-7057PR-171
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsRejection of renal transplantationSolid tumoursAngioimmunoblastic T-cell Lymphoma +[26] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2012/07/20
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOnyx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesOnyx Pharmaceuticals IncAmgen Europe BvBeOne Medicines Ltd +[7] 
Inactive CompaniesDana-Farber Cancer InstituteWeill Medical College of Cornell UniversityUniversity Of Rochester +[17] 
Active IndicationsRejection of renal transplantationMultiple Myeloma
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaGraft vs Host Disease +[24] 

Other Information

ATC CodeL01XG02
Related LinksWikipediaDrugBankKEGG